Skip to main content

ESTUDIO DE MECANISMOS DE RESISTENCIA INTRINSECOS O MEDIADOS POR ELEMENTOS DEL MICROAMBIENTE DE LA MEDULA OSEA A AGENTES ANTI-MIELOMA MULTIPLE

PI19/01384

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
Execution centre INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands

  • Díaz-Tejedor, A.
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Lorenzo-Mohamed, M.
  • González-Rodríguez, M.
  • Castellanos, B.
  • Sotolongo-Ravelo, J.
  • San-Segundo, L.
  • Corchete, L.A.
  • González-Méndez, L.
  • Martín Sánchez, Montserrat
  • Mateos, M. V.|||0000-0003-2390-1218
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Garayoa, M.
  • Paíno, T.
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients' samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

  • García Gómez, Antonio
  • Li, Tianlu|||0000-0001-7152-4870
  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Martín Sánchez, Montserrat
  • San Segundo, Laura|||0000-0003-2391-5935
  • Muntión, Sandra|||0000-0001-7164-0767
  • Morales Urteaga, Xabier|||0000-0003-0303-9958
  • Ortiz de Solórzano, Carlos|||0000-0001-8720-0205
  • Oyarzabal, Julen|||0000-0003-1941-7255
  • San José Enériz, Edurne|||0000-0001-5786-5273
  • Esteller, M|||0000-0003-4490-6093
  • Agirre, Xabier|||0000-0002-6558-9560
  • Prosper, Felipe|||0000-0001-6115-8790
  • Garayoa, Mercedes|||0000-0003-2194-2841
  • Ballestar, Esteban|||0000-0002-1400-2440
Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to reverse MBD.